new
   Indications of Zongertinib
502
Sep 28, 2025

Zongertinib is a novel kinase inhibitor recently granted accelerated approval by the U.S. FDA. As a targeted therapeutic drug for specific patients with non-small cell lung cancer (NSCLC), key information such as its indications, specifications, characteristics, and storage methods is of great importance for clinical use.

Indications of Zongertinib

Core Indications

Zongertinib is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

The tumor harbors activating mutations in the tyrosine kinase domain of HER2 (ERBB2), confirmed by an FDA-approved detection method.

The patient has received prior systemic therapy.

Use Restrictions

It is not indicated for patients without HER2 mutation testing or patients with squamous NSCLC.

Eligible populations must be selected through companion diagnostics (e.g., Oncomine™ Dx Target Test).

Specifications and Characteristics of Zongertinib

Specification and Characteristic Features

Dosage Form: Oral film-coated tablets, which are oval biconvex tablets for ease of swallowing by patients.

Specification and Content: Each tablet contains 60mg of zongertinib—this is currently the only specification of the drug.

Appearance Features

Color: Yellow.

Imprint: One side is imprinted with "L6", and the other side is imprinted with the Boehringer Ingelheim company logo.

Surface Property: Film-coated, with a smooth and uniform surface.

Formulation Composition

Active Ingredient: Each tablet contains 60mg of zongertinib.

Excipients: Include colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, mannitol, microcrystalline cellulose, and sodium stearyl fumarate.

Coating Ingredients: Include yellow iron oxide, glyceryl monocaprylate and caprate, polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide.

Storage Methods of Zongertinib

Temperature Control

Ideal Storage Temperature: 20°C to 25°C (68°F to 77°F).

Allowable Temporary Deviation Range: 15°C to 30°C (59°F to 86°F).

Packaging Features

Packaged in child-resistant bottles.

Each bottle is equipped with two silica gel desiccants to control humidity.

The commercial packaging is a carton containing one bottle with 60 tablets.

Other Precautions

Keep the original packaging intact and protect from moisture.

Keep away from direct sunlight and heat sources.

Store out of the reach of children.

Do not store the drug in humid environments such as bathrooms.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Zongertinib(Hernexeos)
Treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC) harboring HER2 TKD activating mutations following prior systemic therapy.
RELATED ARTICLES
How to Purchase Zongertinib

Zongertinib is a targeted therapeutic agent for non-small cell lung cancer (NSCLC) harboring activating mutations in...

Saturday, October 11th, 2025, 15:03
Indication of Zongertinib

Zongertinib is a novel kinase inhibitor recently granted accelerated approval by the U.S. FDA. As a targeted therapy...

Saturday, October 11th, 2025, 14:58
How to Use Zongertinib

Zongertinib is a novel kinase inhibitor indicated for the treatment of adult patients with unresectable or...

Saturday, October 11th, 2025, 14:34
Precautions for Zongertinib Administration

Zongertinib is a kinase inhibitor that targets activating mutations in the tyrosine kinase domain of HER2 (ERBB2)....

Saturday, October 11th, 2025, 14:31
RELATED MEDICATIONS
Capmatinib
Treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14...
TOP
1
Zongertinib
Treatment of adult patients with advanced non-squamous non-small cell lung...
TOP
2
Crizotinib
Certain ALK- or ROS1-positive cancers in adults and children.
TOP
3
Dacomitinib
​A kinase inhibitor indicated for the first-line treatment of metastatic...
Cemiplimab
PD-1 inhibitor for advanced cutaneous squamous cell carcinoma, basal cell...
Adagrasib
Locally advanced or metastatic NSCLC harboring KRAS G12C mutation who have...
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved